Background The long-term trajectories of estimated glomerular filtration rate (eGFR) and their relation to early proteinuria ...
Objectives To evaluate the performance of Systemic Lupus Erythematosus Risk Probability Index (SLERPI) in patients with SLE using a Chinese cohort. Methods The Chinese cohort included 352 patients ...
Objective To evaluate the efficacy of mepacrine (MC) as an add-on therapy in patients with SLE unresponsive to hydroxychloroquine (HCQ)-containing regimens at 6 months after MC introduction. Methods ...
Proteomic analysis reveals angiogenesis-related plasma proteins associated with pre-eclampsia in SLE
Objective Delivery of a small for gestational age (SGA) infant is a common pregnancy complication among women with SLE. Although disease activity and autoantibodies such as anti-Smith and ...
Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been ...
Haematologic involvement in patients with systemic lupus erythematosus (SLE) is very common. The principal cytopenias in lupus result in anaemia, white cell deficits and thrombocytopenia. Anaemia may ...
22 Historical aspects of B-cell depletion in SLE (8 October, 2025) ...
Case 1: A 35-year-old female with SLE and planning IVF pregnancy In October 2024 a 35-year-old female with systemic lupus erythematosus (SLE) was reviewed for planning of in vitro fertilization (IVF) ...
Background Mycophenolic acid (MPA) is recommended for the treatment of lupus nephritis (LN). However, the high pharmacokinetic (PK) variability of MPA contributes to its suboptimal efficacy and an ...
Objective Patients with SLE have a well-known increased risk of major comorbidities, although they are also very heterogeneous in terms of the prevalence of comorbid conditions. The relationships of ...
Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib ...
CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results